- Home
- CET vs AGIO Comparison
CET vs AGIO Comparison
Compare CET & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CET | AGIO |
|---|---|---|
| Founded | 1929 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CET | AGIO |
|---|---|---|
| Price | $52.20 | $28.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | 42.2K | ★ 1.4M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.40 | N/A |
| Revenue | $27,062,484.00 | ★ $44,791,000.00 |
| Revenue This Year | N/A | $27.83 |
| Revenue Next Year | N/A | $134.79 |
| P/E Ratio | $7.02 | ★ N/A |
| Revenue Growth | 15.78 | ★ 36.26 |
| 52 Week Low | $40.24 | $22.24 |
| 52 Week High | $52.44 | $46.00 |
Technical Indicators
Market Signals| Indicator | CET | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 52.59 |
| Support Level | $51.06 | $26.25 |
| Resistance Level | $52.25 | $28.87 |
| Average True Range (ATR) | 0.58 | 1.05 |
| MACD | -0.00 | 0.21 |
| Stochastic Oscillator | 91.55 | 72.88 |
Price Performance
Historical ComparisonAbout CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.